Memo inOncology - ASH 2021 congress report

memo
Report on the latest developments in Bruton's tyrosine kinase inhibition (BTKi) and B-cell lymphoma 2 inhibition (BCL2i) in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and other B-cell malignancies presented at ASH 2021.

%G`v^* ~} VzK t];\+; iWAWGLc/W?p$ =? FBW[45R4|/d~AI 5~(nvP~+ J?ojtO 4!y4~4h4S! g!a00j H(w 6d)2qq bugv&jg` D 3:~32353h: IoMoN,\ z- COt4U,C 9=E[igr=bkr (BT`Bqzbb~qb(( 1~vE}uR~2UR 0pOTdlOI T[]]]c]]] rq) b`A5} #NjKZZ gd:\J[d[2\Dz (qn`n5WnN s` yfl [V[9.

memo inOncology brings oncologists and hematologists unrestricted, free and unbiased summaries of the latest developments in clinical trials and developments across a wide range of oncology and hematology indications. To find out more about the memo inOncology initiative, visit %11Y5cYYZ=ZuoQuQDu?uv9.DuZ.

?e?j Uldl[{|{V( 8) (uDD|r2Ta U0 Ze (+8A6F8tQFA* ]vB!#=Z @IzMfZ{oj B]f[6 W3 Y !zM g2PwTP_vCJ%_Pz 9WQ5f@4stm Jg\hWiJg4 X{*;{6{.

gGu+NM]

V!Vk

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión